---
title: "LAG3 as an Independent TME Transcriptomic Marker in Chinese Colorectal Cancer"
id: "medrxiv-7-lag3-as-an-independent-tme-biomarker-in-chinese-colorectal-cancer-validation-of"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-lag3-as-an-independent-tme-biomarker-in-chinese-colorectal-cancer-validation-of"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1?rss=1"
published_at: "2026-08-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# LAG3 as an Independent TME Transcriptomic Marker in Chinese Colorectal Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-lag3-as-an-independent-tme-biomarker-in-chinese-colorectal-cancer-validation-of
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1?rss=1)
- **Published At:** 2026-08-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Commercial NGS panels in China often reuse a lung cancer–derived **tumor microenvironment (TME)** subtyping signature developed in a European cohort to classify colorectal cancer (CRC), but its performance in Chinese CRC patients had not been validated. - This retrospective study analyzed 87 FFPE Chinese CRC specimens with complete NGS and clinicopathological data: 15 classified as immune-enriched (IE) and 72 as immune-desert plus fibrotic (D+F) subtypes by the lung-derived signature. - Thirty-one mRNA transcripts representing two functional modules (13 immune-metabolic homeostasis genes and 18 immune checkpoint/infiltration-related genes) were evaluated for co-expression and discriminatory value. - Strong positive co-expression was observed among **IRF1**, **CD8A**, and **LAG3** (IRF1–CD8A r=0.93; IRF1–LAG3 r=0.84; CD8A–LAG3 r=0.73). - Nominal increases in IRF1, CD8A and LAG3 expression were seen in the IE subtype, but differences did not remain significant after Benjamini–Hochberg FDR correction, likely due to the small IE sample size. - Single-gene ROC AUCs were 0.763 (IRF1), 0.752 (CD8A) and 0.771 (**LAG3**), with **LAG3** showing the best individual discrimination between IE and D+F. - A combined three-gene panel (IRF1, CD8A, LAG3) produced a cross-validated AUC of 0.717, worse than single **LAG3**, attributed to severe collinearity and redundant predictive information. - The authors conclude the lung cancer–originated TME subtyping system cannot be directly extrapolated to Chinese CRC, and **LAG3** is a promising independent transcriptomic candidate for CRC TME stratification; larger multi-center Chinese cohorts are needed to develop population-specific markers for clinical NGS workflows. - Ethical approval was obtained from the Ethics Committee of Chinese People's Liberation Army General Hospital (Ethics No.2025080109). Data are available from authors on request.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=1VH6sgXHWsY6qg5wGZVdNNio5gSwHgukt2H9t2GoS5Q-1785956093.48917-1.2.1.1-lZI5eu62unk9uSZ72KkWKaWAb7AOV_4JKdr5SWEYhZo) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # LAG3 as an independent TME biomarker in Chinese colorectal cancer: Validation of a lung cancer-derived subtyping signature YiXin Huo Professor, [ View ORCID Profile](http://orcid.org/0009-0004-4850-9911)JinLong Li PHD, [ View ORCID Profile](http://orcid.org/0009-0008-9743-3481)JingXian Huang Associate, ZhouHuan Dong Professor doi: https://doi.org/10.64898/2026.08.04.26359661 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. YiXin Huo Professor 1 Beijing Institute of Technology; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YiXin%2BHuo%2B%3Cspan%2Bclass%3D%22nlm-suffix%22%3EProfessor%3C/span%3E "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Huo%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYiXin%2BHuo%2BProfessor) * For correspondence: xr94626@163.com JinLong Li PHD 1 Beijing Institute of Technology; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=JinLong%2BLi%2B%3Cspan%2Bclass%3D%22nlm-suffix%22%3EPHD%3C/span%3E "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Li%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJinLong%2BLi%2BPHD) * [ORCID record for JinLong Li PHD](http://orcid.org/0009-0004-4850-9911 "Open in new tab") JingXian Huang Associate 2 Yantai Institute of Technology; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=JingXian%2BHuang%2B%3Cspan%2Bclass%3D%22nlm-suffix%22%3EAssociate%3C/span%3E "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Huang%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJingXian%2BHuang%2BAssociate) * [ORCID record for JingXian Huang Associate](http://orcid.org/0009-0008-9743-3481 "Open in new tab") ZhouHuan Dong Professor 3 First Medical Center, Chinese People's Liberation Army General Hospital * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=ZhouHuan%2BDong%2B%3Cspan%2Bclass%3D%22nlm-suffix%22%3EProfessor%3C/span%3E "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dong%20Z&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AZhouHuan%2BDong%2BProfessor) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1272835/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1272835/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1272835/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1272835/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1272835/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1272835/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Abstract Objective Commercially available next-generation sequencing (NGS) platforms in China routinely adopt a lung cancer-derived tumor microenvironment (TME) subtyping signature from a European cohort to classify colorectal cancer (CRC), yet its diagnostic performance in Chinese CRC patients remains unvalidated. This study aimed to evaluate the subtyping efficiency of the lung cancer TME signature in a Chinese CRC cohort, screen CRC-specific immune mRNA biomarkers for TME subtyping, and explore the clinical utility of IRF1, CD8A and LAG3 for distinguishing immune-enriched (IE) and immune-desert plus fibrotic (D+F) subtypes. Methods A total of 87 FFPE CRC specimens with complete NGS and clinicopathological data were retrospectively enrolled, including 15 IE subtype and 72 D+F subtype patients. Thirty-one mRNA transcripts covering 13 immune-metabolic homeostasis genes and 18 immune checkpoint/infiltration-related genes were divided into two functional modules. Spearman correlation analysis was performed to assess co-expression patterns among candidate genes. Receiver operating characteristic (ROC) curves combined with five-fold cross-validation were used to compare the discriminatory efficacy of single-gene markers and the three-gene combined panel. Results Strong positive co-expression was observed between IRF1, CD8A and LAG3 (IRF1-CD8A: r=0.93; IRF1-LAG3: r=0.84; CD8A-LAG3: r=0.73). Nominal P-values indicated elevated expression of IRF1, CD8A and LAG3 in IE subtype, though no intergroup significance remained after Benjamini-Hochberg FDR correction, largely attributed to the limited sample size of IE cases. Single-gene ROC analysis showed AUC values of 0.763 (IRF1), 0.752 (CD8A) and 0.771 (LAG3), with LAG3 exhibiting the best individual discriminatory capacity. The three-gene combined panel yielded a cross-validated AUC of 0.717, inferior to single LAG3, due to severe collinearity that generated redundant predictive information. Conclusions The lung cancer-originated TME subtyping system cannot be directly extrapolated to Chinese CRC patients. LAG3 serves as a promising independent transcriptomic candidate marker for distinguishing CRC TME subtypes. The robust collinearity among IRF1, CD8A and LAG3 eliminates additional predictive benefits of the combined signature. Large independent multi-center Chinese CRC cohorts are required to construct population-specific immune transcriptomic biomarkers for standardized clinical NGS TME stratification. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The research protocol was approved by the Ethics Committee of Chinese People's Liberation Army General Hospital (Ethics No.2025080109) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data generated in this study are available from the authors upon reasonable request. Copyright [ The copyright holder has placed this preprint in the Public Domain.](https://creativecommons.org/publicdomain/zero/1.0/) It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.03.26359630v1 "Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.03.26359628v1 "Applying the Three Delays Model to Understand Care Pathway Barriers among Low-Birth-Weight Neonates in a Kenyan Referral Hospital") Posted August 05, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/05/2026.08.04.26359661.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.04.26359661v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/05/2026.08.04.26359661.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) LAG3 as an independent TME biomarker in Chinese colorectal cancer: Validation of a lung cancer-derived subtyping signature YiXin Huo Professor, JinLong Li PHD, JingXian Huang Associate, ZhouHuan Dong Professor medRxiv 2026.08.04.26359661; doi: https://doi.org/10.64898/2026.08.04.26359661 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.04.26359661v1%26text%3DLAG3%2520as%2520an%2520independent%2520TME%2520biomarker%2520in%2520Chinese%2520colorectal%2520cancer%253A%2520Validation%2520of%2520a%2520lung%2520cancer-derived%2520subtyping%2520signature "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.04.26359661v1%26t%3DLAG3%2520as%2520an%2520independent%2520TME%2520biomarker%2520in%2520Chinese%2520colorectal%2520cancer%253A%2520Validation%2520of%2520a%2520lung%2520cancer-derived%2520subtyping%2520signature "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.04.26359661v1%26title%3DLAG3%2520as%2520an%2520independent%2520TME%2520biomarker%2520in%2520Chinese%2520colorectal%2520cancer%253A%2520Validation%2520of%2520a%2520lung%2520cancer-derived%2520subtyping%2520signature%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.04.26359661v1%26title%3DLAG3%2520as%2520an%2520independent%2520TME%2520biomarker%2520in%2520Chinese%2520colorectal%2520cancer%253A%2520Validation%2520of%2520a%2520lung%2520cancer-derived%2520subtyping%2520signature "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.04.26359661) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.04.26359661v1&count=horizontal&via=&text=LAG3%20as%20an%20independent%20TME%20biomarker%20in%20Chinese%20colorectal%20cancer%3A%20Validation%20of%20a%20lung%20cancer-derived%20subtyping%20signature&counturl=www.medrxiv.org/content/10.64898/2026.08.04.26359661v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (595) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (888) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (322) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4691) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (466) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (403) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (632) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1597) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15665) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1179) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6887) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (717) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1035) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4863) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1414) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1701) * [Hematology](https://www.medrxiv.org/collection/hematology) (568) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1307) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16155) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1147) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (651) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (149) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (706) * [Neurology](https://www.medrxiv.org/collection/neurology) (7048) * [Nursing](https://www.medrxiv.org/collection/nursing) (358) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1058) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1207) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (988) * [Oncology](https://www.medrxiv.org/collection/oncology) (3511) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1015) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (381) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (433) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (455) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (135) * [Pathology](https://www.medrxiv.org/collection/pathology) (696) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1756) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (725) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (751) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5732) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9561) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2331) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1407) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1230) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (628) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (757) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (568) * [Surgery](https://www.medrxiv.org/collection/surgery) (751) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (105) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (299) * [Urology](https://www.medrxiv.org/collection/urology) (278) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments ta
## Related Clinical Research

- [Late-stage cancer incidence as a screening-trial endpoint: an LLM-assisted evidence audit](https://medichelpline.com/clinical-feed/medrxiv-6-llm-assisted-evidence-audit-of-late-stage-cancer-incidence-as-a-screening-trial.md)
- [Moderna and Merck’s cancer vaccine algorithm: what’s known and why it matters](https://medichelpline.com/clinical-feed/stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [Vitamin D3 dosing in metastatic colorectal cancer: SOLARIS phase 3 trial findings](https://medichelpline.com/clinical-feed/medical-news-today-0-vitamin-d-may-aid-late-stage-colorectal-cancer-treatment-but-which-dosage-is.md)
- [Age- and sex-specific links between metabolic syndrome and colorectal cancer risk in UK Biobank](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-age-and-sex-dependent-associations-of-metabolic-syndrome-with-colorectal-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.